US/UK/Canada

Share

Pick a time period -

Modus Therapeutics presents at småbolagsdagarna

Stockholm, Friday, June 10, 2022. Modus Therapeutics Holding AB ("Modus") announces that the company will participate at aktiespararnas event småbolagsdagarna on June 13, 2022.On June 13th at 12:00 at the event "Småbolagsdagarna by Aktiespararna", Modus' CEO John Öhd will present the company and the ambition to advance sevuparin in clinical development as a "first-in-class" drug candidate in treatment for sepsis and septic shock. Modus invites you as a journalist, analyst and shareholder to take part in the live broadcast at www.aktiespararna.se/tv/live . The event is open to everyone

Modus Therapeutics Updates on Sevuparin Phase 1b Clinical Trial Timelines

STOCKHOLM, SWEDEN – 25 May 2022: Modus Therapeutics Holding AB, a biopharma company focused on the clinical development of its proprietary asset sevuparin for the treatment of sepsis/septic shock and other conditions with systemic inflammation, provides an update on its ongoing Phase 1b LPS-challenge study and its other clinical activities with sevuparin.Modus has observed that the ongoing effects of the Covid-19 pandemic throughout spring have slowed down enrolment for the Phase 1b trial, causing a delay to the anticipated timelines. This is largely attributed to subjects being unable to

Modus Therapeutics publishes interim report for the first quarter 2022

STOCKHOLM, SWEDEN - 16 May 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the first quarter 2022. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.The first quarter in figures · The loss after tax amounted to TSEK 3 065 (1 428). · The loss per share amounted to SEK 0,19 (0,17). · The cash flow from current operations was negative in the amount of TSEK 7 545 (1 166). Important events during the quarter · Modus presented at Erik Penser

Modus Therapeutics secures access to bridge financing from Karolinska Development

STOCKHOLM, SWEDEN - 12 May 2022: Modus Therapeutics Holding AB (“Modus”) announces that it has secured access to bridge financing of up to SEK 11.5 million from its largest shareholder, Karolinska Development. Access to this potential funding will ensure that momentum of clinical development of the company’s lead asset, sevuparin, for the treatment of sepsis is sustained. This includes the planning for the forthcoming Phase 2a study in patients with sepsis that is expected to begin before the end of 2022.John Öhd, CEO of Modus Therapeutics, said: “We are pleased to have secured access to

Annual General Meeting in Modus Therapeutics Holding AB (publ)

Today, the annual general meeting of 2022 was held in Modus Therapeutics Holding AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.modustx.com).Modus Annual General Meeting on 11 May 2022 resolved in accordance with the following:  · That no dividend would be paid. · To discharge the board members and the managing director from liability with respect to their management of the company for the financial year 2021. ·

New publication date for Modus Therapeutics’ interim report for the first quarter

Stockholm, Sweden–April 22[th] 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby announces that the publication of the company's Q1 report will take place on May 16, 2022. The previously announced date was May 9, 2022.For more information on Modus Therapeutics, please contact: John Öhd, VD, Modus Therapeutics Telefon: +46 (0) 70 766 80 97 E-post: john.ohd@modustx.com Certified Adviser Svensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se *** About Modus Therapeutics and sevuparin Modus Therapeutics is a Swedish

Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2021

Stockholm, Sweden–April 19[th] 2022: Modus Therapeutics Holding AB (publ) (”Modus Therapeutics”) announces today that the company is publishing the annual report for 2021.The annual report is now available to download at the company’s website: https://www.modustx.com/investors/financial-reports.html For more information on Modus Therapeutics, please contact: John Öhd, VD, Modus Therapeutics Telefon: +46 (0) 70 766 80 97 E-post: john.ohd@modustx.com Certified Adviser Svensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se *** About Modus

Notice to Annual General Meeting in Modus Therapeutics Holding

The shareholders of Modus Therapeutics Holding AB (publ) are invited to the annual general meeting on Wednesday, 11 May 2022, at 14.00 p.m., at Advokatfirman Vinge’s offices at Smålandsgatan 20, in Stockholm, Sweden.Right to participate and notice A shareholder who wishes to participate in the meeting must: · be recorded in the share register maintained by Euroclear Sweden AB relating to the circumstances on Tuesday, 3 May 2022, and · notify the company of their intention to participate in the meeting not later than Thursday, 5 May 2022. The notification shall be made by

Modus Therapeutics to present at the Erik Penser Bank Health Care Day

Stockholm, Thursday, February 24, 2022. Modus Therapeutics Holding AB ("Modus") announces that the company will participate at the Erik Penser Bank Health Care Day on February 24, 2022.Modus CEO John Öhd presents today at Erik Penser Bank's Theme Day-Health Care. He will present Modus and will talk more about our ambition to advance sevuparin in clinical development as a "first-in-class" drug candidate in treatment for sepsis and septic shock. Thursday 24/2 Modus to present at approx. 15:50 You can reach presentations from the day via this link, and Modus presentation will be

Modus Therapeutics publishes year-end report for 2021

STOCKHOLM, SWEDEN - 22 February 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes a year-end report for 2021. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the year-end report.John Öhd, Modus Therapeutics' CEO, commented:  "This has been a transformative year for Modus, as we set out and executed on our new strategy to focus sevuparin development on sepsis, launched our oversubscribed IPO on First North, and rapidly progressed into a Phase 1b clinical trial that evaluates sevuparin during LPS

Modus Therapeutics sums up the significant progress on key milestones during 2021, including IPO on First North Stockholm

Stockholm, Sweden – January 14[th] 2022: Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs, sums up its significant progress towards its business goals for 2021, which primarily aimed to advance sevuparin to clinical development as a “first-in-class” drug candidate in the treatment for sepsis and septic shock.“This has been a transformative year for Modus,” commented Modus Therapeutics’ CEO John Öhd. “We’re thrilled to see our new strategy for sevuparin in sepsis/septic shock already starting to pay off, as we transitioned from

Modus Therapeutics participates in Aktier Live Sessions

Stockholm, Tuesday, December 14, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company participates in today’s Aktier Live Sessions at 18:00.Modus' CEO John Öhd and CFO Claes Lindblad will be interviewed by Aktier Live Sessions Jonathan Furelid on Tuesday, December 14 at 18:00. The interview is streamed live with the opportunity to ask questions to the company directly in the chat. The company tells of an eventful year during which, among other things, the company was listed on the Nasdaq First North Growth market and started the first clinical study in the planned sepsis

Modus Therapeutics comments on the start of the first clinical study in the planned sepsis program

Stockholm, Thursday, December 2, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company is set to participate in a live broadcast today at 14:00.Modus' CEO John Öhd will participate in a live broadcast via Infront Direkt Studios today December 2 at 14:00, to comment on the start of the company's clinical Phase 1b LPS provocation study as communicated in yesterday's published press release. To follow the live broadcast, click here  For more information on Modus Therapeutics, please contact: John Öhd, VD, Modus Therapeutics Telefon:

First sevuparin dose administered in Modus Therapeutics’ Phase 1b LPS provocation study

STOCKHOLM, SWEDEN – December 1, 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs, announces that the first clinical trial participant has been dosed with sevuparin in the company's clinical Phase 1b LPS provocation study.The randomized, placebo-controlled Phase 1b study will evaluate the effects of sevuparin on the symptoms of healthy volunteer participants who have been injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and blood (systemic inflammation). Provocation

Modus Therapeutics publishes interim report for the third quarter 2021

STOCKHOLM, SWEDEN - 18 November 2021: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the third quarter 2021. The interim report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.The third quarter in figures · The loss after tax amounted to TSEK 4 441 (697). · The loss per share amounted to SEK 0,30 (0,12) · The cash flow from current operations was negative in the amount of TSEK 4 226 (942) The first nine-months in figures · The loss after tax amounted

Modus Therapeutics Receives Regulatory Approval to Start a Phase 1b Clinical LPS Challenge Study with Sevuparin in the Netherlands

STOCKHOLM, SWEDEN – 9 November 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, announces that it has received the approval for its planned phase 1b clinical trial with sevuparin by the competent authorities in the Netherlands.The planned randomized, placebo-controlled Phase 1b study will evaluate the effects of intravenous sevuparin on the dermal and systemic lipopolysaccharide (LPS) induced inflammatory responses in healthy volunteers. The LPS challenge is a well-established model used to characterize the

Modus Therapeutics participates in Småbolagspodden

Stockholm, Wednesday, October 27, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company participates in the latest episode of Småbolagspodden.Modus’ CEO John Öhd and CFO Claes Lindblad are interviewed by Småbolagspodden's Jonathan Furelid. Listen in to the discussions on sepsis, one of the most prevalent death causes globally and Modus' development of sevuparin for sepsis and other patients with high unmet medical needs, as well as a further look into what the future plans for Modus look like. To listen to the episode via Småbolagspodden, click here 

Modus Therapeutics engages Lago Kapital as a liquidity guarantor

STOCKHOLM, SWEDEN - 21 October 2021: Modus Therapeutics Holding AB (“Modus Therapeutics”) announces that it has engaged Lago Kapital as a liquidity guarantor for the company's share. The liquidity guarantee starts to run from 22 October 2021.In its assignment as liquidity guarantor, Lago Kapital will ensure the opportunity to trade in the company's shares by continuously placing trading items on each buy and sell page in the order book. This is in accordance with Nasdaq First North Growth Market regulations regarding liquidity guarantee and means that the liquidity guarantor quotas the

Modus Therapeutics participates in the Biostock Life Science Summit 2021

Stockholm, Tuesday 19 October 2021. Modus Therapeutics Holding AB ("Modus") announces today that the company's CEO John Öhd will participate in Biostock's annual conference Biostock Life science summit to update on the company's key activities and expected milestones in the development work of the drug candidate sevuparin.The presentation will take place at 10:20 on 21 October. Follow this link to the presentation  For more information on Modus Therapeutics, please contact: John Öhd, VD, Modus Therapeutics Telefon: +46 (0) 70 766 80

Modus Therapeutics - Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus’ Future Clinical Development in Sepsis/septic shock

STOCKHOLM, SWEDEN – 12 October 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, announces that Symbiosis Pharmaceutical Services Ltd (“Symbiosis”), a specialist contract manufacturing organization (CMO), has started manufacturing sevuparin drug product securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation. This follows a recent drug supply agreement between Modus and Symbiosis covering the drug product needs for the Phase II

Modus Therapeutics Appoints Key Scientific Advisors

STOCKHOLM, SWEDEN – 23 September 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, welcomes a panel of key scientific advisors – Professor Eddie Weitzberg, Professor Lennart Lindbom and Professor Mats Wahlgren from the Karolinska Institutet – who will support the company’s future development strategy for sevuparin for sepsis/septic shock and other conditions where systemic inflammation is involved.Lennart Lindbom is Professor of Physiology at the Department of Physiology and Pharmacology at Karolinska

Modus Therapeutics participates in FS markets Investment Meeting-Live on September 23rd

On Thursday, 23 September 2021 at 5.30 pm, Modus Therapeutics AB (“Modus”) will participate in FS Markets Investerarmötet-Live (Investment Meeting-Live). Modus CEO John Öhd will present the company and discuss upcoming plans.Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition. Investor Meeting-Live is a live webcast seminar. The presentation will be followed by a question-and-answer session where you can ask

Modus Therapeutics publishes interim report for the second quarter 2021

STOCKHOLM, SWEDEN - 19 august 2021: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the second quarter 2021. The interim report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.The second quarter in figures · The loss after tax amounted to TSEK 2,533 (1,698). · Cash flow from operating activities amounted to TSEK -2,299 (-2,267) · Cash and cash equivalents amounted to TSEK 3,830 (4,395) The first half-year in figures · The loss after tax amounted to

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media